RNCOS Releases a New Report- Booming Clinical Trials Market in IndiaBy: Shushmul Maheswari
|
RNCOS Releases a New Report- Booming Clinical Trials Market in India
|
Write a Review
Add to My Favorite
Refer it to Friend
Report Broken Link
|
RNCOS has recently added a new Market Research Report titled, “Booming Clinical Trials Market in India” to its report gallery. According to our research report, “Booming Clinical Trials Market in India”, India promises to be one of the hottest destinations for conducting global clinical research, owing to a huge patient pool representing both chronic and infectious diseases, easy recruitment of patients, and high cost savings.
India presently occupies a very small pie of the global opportunity. The total number of clinical trials in India stood at 221 in 2007, which equates to less than 2% of the global clinical trials. With all major pharmaceutical/biotech companies and CROs establishing their presence in India, the number of clinical trials in the country is expected to grow several folds in the next five years. The country is projected to conduct nearly 5% of the global clinical trials by 2012. However, to achieve its goal of becoming a global hub of clinical trials, the country has to overcome challenges like unethical trials, delay in trial approval, inappropriate protection of clinical data, and lack of Good Clinical Practice (GCP) certified sites and investigators.
Surging clinical trials market in India will create enormous opportunities for a number of associated industries, including IVD market, education sector and clinical data management.
“Booming Clinical Trials Market in India” gives an extensive and objective analysis on the Indian clinical trials market. It investigates the advantages/disadvantages India has in becoming a global clinical trials hub. The report exhaustively evaluates and compares the key factors that drug companies and CROs look before outsourcing clinical trials to a country. These include parameters such as patient pool, regulatory environment, cost, infrastructure, human resources and past performance in conducting clinical trials. Thus, this analytical study serves as a useful guide for drug manufacturers, CROs, consultants and investors who are planning to enter the Indian clinical trials market.
Our report provides forecasts on
- Size of global clinical research outsourcing market
- Size of Indian clinical research outsourcing market
- Number of clinical trials in India
- Number of patients expected to participate in clinical trials in India
- Clinical trials infrastructure and professionals in India
- Healthcare indicators in India
Key questions answered in the report
- Why are drug manufacturers outsourcing clinical trials?
- Where and how many clinical trials are being outsourced?
- Where dose India stand in the global clinical trials market?
- How big is the clinical trials opportunity in India?
- How much does it cost on hiring personnel for various clinical research processes, rent and utilities in India as compared to other countries?
- How does clinical trials infrastructure and staff in India vary from other countries?
- What are various government regulations/guidelines for conducting clinical trials in India?
- What are the Future trends predicted to shape the clinical trials market in India?
- How is the clinical trials market impacting associated industries?
Key players analyzed in the report
This section provides business overview on prominent players in the Indian clinical research market like Syngene International Ltd, Quintiles Research (India) Private Limited, Lambda Therapeutic Research Ltd, Vimta Labs Limited and Veeda Clinical Research - India.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM564.htm
Check DISCOUNTED REPORTS on: http://www.rncos.comhttp://www.rncos.com/ |
|
| Keywords |
Indian clinical trials market |
| Category |
Health and Fitness |
| Submission Date |
May 21, 2009 |
| Article Contact Name |
Shushmul Maheswari || send email to Shushmul Maheswari
|
|
Other links at Health and Fitness |
| 1. |
Health-conscious World Gobbling Organic Food: RNCOS
|
|
|
The organic food market is gaining a strong foothold in global food markets due to the fact that global population is becoming more health conscious and is paying more attention to the food it eats. Additionally, environmental and animal health issues, improved taste, and better quality of the food are other factors which are driving the world organic food market. As a result, the world organic food and beverages market grew by about 18% in 2007 over the previous year and is projected to reach around US$ 70 Billion by 2010. These are the findings of our latest research report, “Emerging Organic Food Markets”.
The report states that North America and Europe have large share and accounted for around 96% of the global organic food and beverage industry revenue in 2007. In North America, demand of organic food exceeds its supply which eventually increases the import of organic food and beverage. The European organic food industry is also experiencing a supply shortage. In terms of market size, the US has the maximum share in the world organic food market with sales around US$ 20 Billion in 2007.
However, various other developing markets like Belgium, Netherlands, Korea and Taiwan are also increasing their share in the world organic food market. Governments of these countries are also promoting organic food production to meet increasing demand.
The Asia-Pacific region accounts for the least share in total world organic food and beverages market. But high consumption of organic food and drinks as well as the shifting of trend towards natural food is boosting the growth of the organic food market in the region.
“Emerging Organic Food Markets” gives an extensive and analytical study on the organic food and beverages market. It provides past and current data and discusses the market trends in detail in various regions.
This report highlights the future trends and evaluates the drivers, consumer behavior, developed, developing and emerging markets, and key players to give complete overview on the market.
About RNCOS:
RNCOS, incorporated in the year 2002, is an industry research firm. It has a team of industry experts who analyze data collected from credible sources. They provide industry insights and analysis that helps corporations to take timely and accurate business decision in today's globally competitive environment.
For more information visit: http://rncos.com/Report/IM152.htm
Current Industry News: http://www.rncos.com/Blog/
|
| 2. |
RNCOS Forecasts 18% Growth in Ukraine Pharma Market
|
|
|
According to our recent report, “Ukraine Pharma - New Opportunities for Growth”, Ukraine represents one of the fastest growing and lucrative markets in Europe, with its revenue exceeding US$ 2 Billion in 2007.
The market is largely driven by the increasing pharmaceutical spending as a result of robust economic growth of the country, as well as the increasing proportion of high-priced drugs in the overall pharma market. Between 2001 and 2007, average disposable income in Ukraine grew more than six-fold, thereby increasing drug spending strongly.
The proportion of high-priced drugs is also growing rapidly in Ukraine, with the average unit price of drugs increasing by around 20% in 2007 as compared to the previous year. In fact, in the hospital segment, the average unit price of drugs increased by more than 33%, thus fuelling growth in sales value despite a sharp decline in sales volume.
The future prospects of the market also seem very encouraging. The Ukrainian government recently proposed a reform to introduce a compulsory public health insurance scheme with the aim to make expensive drugs affordable to masses. Ukraine still lacks a public reimbursement scheme but with the introduction of public insurance scheme, the affordability of quality drugs, which were used to be paid largely out of pocket till now, will increase significantly. This will considerably boost the sales value and volume. The research report expects the Ukraine pharma market to grow at a CAGR of around 18% through 2012.
“Ukraine Pharma - New Opportunities for Growth” gives an extensive and objective analysis on the pharmaceutical market of Ukraine. The report investigates both the past and present trends in the pharmaceutical market, but its focus is on the future trends shaping the industry. The report thoroughly investigates the performance of both the retail and hospital segments of the pharmaceutical market. Based on various present and future indicators, the future of vaccines has been fully analyzed. The report thus gives valuable information to manufacturers/investors preparing to enter the Ukrainian pharmaceutical market.
For more information visit: http://www.rncos.com/Report/IM161.htm
Current Industry News: http://www.rncos.com/Blog/
|
| 3. |
Aging Population & Healthcare Reforms Driving Russian Pharma
|
|
|
According to our new research report, “Russian Pharma Sector Analysis”, the pharmaceutical market in Russia has very bright future as it will grow at a CAGR of nearly 14% by 2012. The positive outlook for pharmaceutical market is based on the high proportion of elder people (65 years and above) in the overall population.
The proportion of aging population in Russia mounted to 20.4 Million in 2007 from 18.5 Million in 2001, indicating to the enormous growth opportunities for the pharmaceutical industry, said the RNCOS report. Moreover, the share of aging population is anticipated to further rise with the improvement in the Russian healthcare system.
With expanding share of aging population, the prevalence of age-related diseases such as arthritis, diabetes and heart ailments is also increasing that will fuel the demand for medicines used in the treatment of these diseases. The dependency ratio of aged people on the working population is also growing with rising number of senior citizens in the country.
Besides, the reforms introduced by the Russian government in the healthcare sector have given fresh impetus to the pharmaceutical sector. Poor state of the healthcare system and declining population have prompted the government to reform the healthcare system and increase spending.
“Russian Pharma Sector Analysis” provides comprehensive research and objective analysis on the growing demand for pharmaceuticals in Russia. It discusses present and past trends to give clear picture of the country’s healthcare and pharmaceutical market. The report also provides brief overview of major players operating in each segment of the market along with the shares of imported and domestic drugs. Rx, OTC and sales structure by ATC group have been analyzed in the context of the Russian pharmaceutical market.
The report also provides forecast on various segments of Russian Pharma Sector, including pharmaceutical market by segments, population aged 65 years & above, commercial drugs segment.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM548.htm
Check DISCOUNTED REPORTS on: http://www.rncos.com
|
| 4. |
Some important Steps to Follow When Choosing a Fitness Program
|
|
|
Embarking upon a new fitness program can be a challenging task. Here are some six steps to ensure you start down the right path to health.
1) What's your starting point? Before embarking that on any fitness program, it is really important that you first evaluate your own level of particular health and fitness. If you have not been well regularly exercising, you should check with your doctor before taking the next step. At the most very least, plan to get start slow and build though your way up.
2) Set your goals. What are you trying to achieve? Weight loss? A more muscular body? Write down short term concrete goals that will guide you. One goal might be to lose ten pounds. Another reason might be to get move up to a more hard level on the real stationary bike. Goals are important for several reasons. They motivate you. They give you something measurable to evaluate your progress. And keeping them short term gives you the ability to more frequently enjoy the wins as you reach a new level.
3) Do what you'll enjoy. It's important that the fitness program you choose actually incorporates activities you will enjoy. If you hate the gym, find a program of home and outdoor based exercises. If you dislike jogging, focus on swimming or biking. The key is to choose activities that won't bore or frustrate you.
4) Mix it up. And speaking of boredom, it's helpful to incorporate a range of activities so you can mix up your workouts. Swim one day, bike the next. Not only does this keep you from falling into a rut, but it also forces your body to adapt to different types of movement and muscle use. For example, a program that alternates swimming with biking will ensure that you are working almost every major muscle in the body.
5) Check your wallet. You need to find a program that falls within any budget constraints you might have. If a gym membership is out of your price range, invest in a program that concentrates on exercises that can be done at home or outside. It makes no sense to invest in a fitness program that emphasizes the use of gym circuit machines if you can't afford the membership.
6) Just do it. This is the key step. After doing all the homework, go for it. Actually get up and start the program you've selected. It's time to get physical and follow through on your fitness goals. Start slow and build intensity gradually. What's the payoff? A future that includes a healthier and happier you. And chances are it's a future that will last longer than if you don't get off the couch.
J.D. Bell is a former fitness and health trainer who, as a first time father at age 45, is very focused on his own longevity
|
| 5. |
RNCOS Releases a New Report- Ukraine Pharma - New Opportunities for Growth
|
|
|
RNCOS has recently added a new Market Research Report titled, “Ukraine Pharma - New Opportunities for Growth” to its report gallery. According to the new research report, Ukraine promises to be one of the most lucrative pharmaceutical markets in the world. In 2007, the Ukrainian pharmaceutical market grew by nearly 21% to register revenues in excess of US$ 2 Billion. The market is characterized by an increasing proportion of imported and high-priced drugs. In 2007, the average unit price of drugs sold in Ukraine increased by nearly 20%, strongly pushing the value of pharmaceutical sales, despite a relatively ordinary growth in sales volume.
The future outlook of the industry also seems very positive as the market is expected to be driven by a number of reforms recently proposed by the government. Factors such as increasing penetration of health insurance and increasing disposable incomes of consumers will also fuel growth. The lack of effective price controls and high margins are also expected to lure foreign players in this market. The country’s unstable political environment, however, will be the biggest hurdle for investments. But overall, the market is expected to grow strongly, exceeding US$ 4.5 Billion in revenues by 2012.
This report gives an extensive and objective analysis on the pharmaceutical market of Ukraine. It investigates both the past and present trends in the market, with its main focus on the future trends shaping the industry. The study discusses the performance of both the retail and hospital segments of the pharmaceutical market in detail and based on various present and future indicators, analyzes the future of these segments. This report gives valuable information to manufacturers/investors planning to enter the Ukrainian pharmaceutical market.
The Report Provides Forecasts on
- Macroeconomic Indicators
- Healthcare Indicators
- Population & Demographics
- Disease Profiles
- Total Pharmaceutical Market
- Retail Pharmaceutical Market
- Hospital Pharmaceutical Market
Key Player Profiling
“Ukraine Pharma - New Opportunities for Growth” provides brief profiling on key players, both domestic and foreign, currently operating in the Ukraine pharmaceutical market. This section describes the revenues and growth of players in the total pharmaceutical market, retail market and hospital market. Performance of key drugs in various segments of the market has also been evaluated. Business profiles of top five players, Berlin Chemie, Sanofi Aventis, Novartis, Arterium and Darnitsa, have also been discussed in this report.
For more information visit: http://rncos.com/Report/IM161.htm
Current Industry News: http://www.rncos.com/Blog/
|
|
|
